

European Journal of Cancer this month published an article on the FIH study in patients with solid tumors conducted with the MPS1 compound NMS-01940153E discovered at NMS Srl.

Nerviano, 13 May 2022_Nerviano Medical Sciences (NMS Srl) a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, is delighted to share the publication on the current issue of the European Journal of Cancer of the first-in-human (FIH) study conducted with the MPS1 inhibitor NMS-01940153E discovered in Nerviano ([Schöffski *et al.*; European Journal of Cancer, Volume 169, 2022](#)).

MPS1, also known as monopolar spindle 1, is a protein kinase which is over-expressed and hyperactivated in different tumors and which plays a critical role in the control of mitosis (cell division) by regulating a process called the Spindle Assembly Checkpoint. NMS Srl started the MPS1 inhibitor program, which resulted in the identification of the innovative and proprietary clinical candidate NMS-01940153E, a molecule with potential for being a first-in-class drug against this target.

NMS-01940153E is a potent and selective inhibitor of MPS1, possessing potent antiproliferative activity against cell lines derived from different tumor types, including breast cancer, colon carcinoma and hepatocellular carcinoma, with a distinct activity profile and different mechanism of action when compared to other mitotic inhibitors currently approved or in the clinic. Tumor growth inhibition observed in preclinical models, associated with a favorable pharmacokinetic and toxicological profile confirmed the selection of NMS-01940153E as a promising Product Candidate for clinical development.

The publication by Schöffski *et al* reports the results of the FIH study where thirty-eight patients were treated with NMS-01940153E by intravenous administration once a week, for 3 consecutive weeks in repeated 28-day cycles to explore safety, pK and early signs of efficacy.

Based on the positive findings of this first study, NMS is currently developing NMS-01940153E in a phase I/II clinical trial in the setting of hepatocellular carcinoma (HCC). Lisa Mahnke, CMO Consultant of NMS stated: "NMS is pleased to continue development of NMS-01940153E in a relevant dosing range in hepatocellular carcinoma for patients with high unmet medical need." This trial (EUDRACT 2020-001002-26) is currently being conducted by NMS at centers of excellence for HCC both in Italy and in Spain.

About Nerviano Medical Sciences

[Nerviano Medical Sciences](#) S.r.l. (NMS Srl) is focused on discovery and clinical development of small molecule NCEs for oncology. We take innovative approaches on novel mechanisms of action and drug targets to bring first- and best-in-class personalized medicines to cancer patients. Our current pipeline consists of NCEs, which all originate from our well validated kinase platform that span from early preclinical to clinical stage projects and which are being developed both in house and with partners.

NMS Srl combines the flexibility of a biotech with the quality of a big pharma. Here, an experienced management team leads a highly skilled staff of professionals with global vision and a broad range of expertise in research, drug discovery and clinical development. We cover the whole range of additional aspects of drug development through the NMS Group affiliate companies, Accelera (AdMet) and NerPharMa (manufacturing). A key strength is our industrially renowned kinase inhibitor drug discovery platform which comprises an ever-evolving chemical collection with broad intellectual property coverage, discovery know-how and technologies which enabled us to out-license IP rights on recently approved innovative medicines such as encorafenib and entrectinib.

NERVIANO MEDICAL SCIENCES

PART OF NMS GROUP

We collaborate with academia and clinical investigators as well as with industrial partners worldwide to advance our programs from early discovery to clinical development of new drugs. We seek further strategic collaborations to develop and commercialize our products in different territories as well as in-licensing opportunities of promising assets for clinical development.

About NMS Group

[NMS Group](#) is the largest oncological R&D company in Italy. With more than 400 employees of whom more than half are highly educated individuals dedicated to innovative research, development and manufacturing. The NMS kinase inhibitor discovery platform as well as the antibody-conjugating payload platform are the driving forces of the group's innovation, securing global recognition of NMS in personalized therapy. Recently entrectinib, originally discovered by NMS, is a targeted kinase inhibitor to treat NTRK1/2/3 and ROS1 dependent solid tumors that was licensed to Ignyta, now a member of the Roche Group, gained approvals for commercialization in all major markets. This is further evident of the competitiveness of the drug discovery platform of NMS Group.

NMS Group has three subsidiaries. NMS S.r.l. is a FIC / BIC focused drug research and development company with a robust pipeline of more than a dozen of anti-cancer projects, and three of the projects are currently in early clinical development. The other two subsidiaries are Accelera, which is a preclinical CRO company, and NerPharMa which manufactures API and drug product supporting clinical developments and commercialization.

Media contact: Sidney Dung Sidney.dung@nmsgroup.it